platinum has been researched along with decitabine in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Appleton, K; Brown, R; Gabra, H; Glasspool, RM; Gore, ME; Halford, SE; Hall, GD; Kaye, S; Mackean, M; McNeish, IA; Paul, J; Pledge, S; Rustin, GJ; Ullah, R; Walker, J; Wilson, RH | 1 |
Chen, M; Fu, X; Han, W; Meng, Y; Nie, J; Wang, X; Wang, Y; Zhang, Y | 1 |
2 trial(s) available for platinum and decitabine
Article | Year |
---|---|
A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer.
Topics: Adaptor Proteins, Signal Transducing; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; MutL Protein Homolog 1; Neoplasm Recurrence, Local; Nuclear Proteins; Ovarian Neoplasms; Platinum | 2014 |
Low Dose Decitabine Combined with Taxol and Platinum Chemotherapy to Treat Refractory/Recurrent Ovarian Cancer: An Open-Label, Single-Arm, Phase I/II Study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biomarkers, Tumor; Decitabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Recurrence; Safety | 2015 |